ProFound AI Risk allows for detection of cancers between screenings based on data from prestigious academic medical center, Karolinska Institutet
Research published in Radiology shows technology significantly outperforms existing breast cancer risk models, accelerating movement towards risk-adaptive screening
NASHUA, N.H., Sept. 15, 2020 (GLOBE NEWSWIRE) — iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced compelling data supporting ProFound AI™ Risk was published in the peer-reviewed journal, Radiology.i ProFound AI Risk is the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation that is personalized for each woman, based solely on a screening mammogram. The technology, which allows for the detection of cancers between screenings, was clinically proven to significantly outperform existing breast cancer risk models.
ProFound AI Risk was created from an exclusive relationship between iCAD and leading researchers at the Karolinska Institutet in Stockholm, Sweden, one of the world’s foremost medical research universities and the home of the Nobel Assembly, which selects the Nobel laureates in Physiology or Medicine. This partnership built upon a previous research agreement whereby researchers at the Karolinska Institutet developed a breast cancer risk prediction model using information identified in mammography images provided by iCAD’s AI solutions.
“ProFound AI Risk and the publication of this supporting